These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 34729904)

  • 21. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic Steatohepatitis: A Review.
    Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
    JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification.
    Panasevich MR; Peppler WT; Oerther DB; Wright DC; Rector RS
    Physiol Genomics; 2017 Aug; 49(8):385-399. PubMed ID: 28600319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease.
    Aqel B; DiBaise JK
    Nutr Clin Pract; 2015 Dec; 30(6):780-6. PubMed ID: 26449892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
    Miura K; Ohnishi H
    World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease.
    Park E; Jeong JJ; Won SM; Sharma SP; Gebru YA; Ganesan R; Gupta H; Suk KT; Kim DJ
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrogenesis Marker PRO-C3 Is Higher in Advanced Liver Fibrosis and Improves in Patients Undergoing Bariatric Surgery.
    Bel Lassen P; Nori N; Bedossa P; Genser L; Aron-Wisnewsky J; Poitou C; Surabattula R; Juul Nielsen M; Asser Karsdal M; Julie Leeming D; Schuppan D; Clément K
    J Clin Endocrinol Metab; 2022 Mar; 107(4):e1356-e1366. PubMed ID: 34905051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
    Schwimmer JB; Johnson JS; Angeles JE; Behling C; Belt PH; Borecki I; Bross C; Durelle J; Goyal NP; Hamilton G; Holtz ML; Lavine JE; Mitreva M; Newton KP; Pan A; Simpson PM; Sirlin CB; Sodergren E; Tyagi R; Yates KP; Weinstock GM; Salzman NH
    Gastroenterology; 2019 Oct; 157(4):1109-1122. PubMed ID: 31255652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence.
    Federico A; Dallio M; Godos J; Loguercio C; Salomone F
    Transl Res; 2016 Jan; 167(1):116-24. PubMed ID: 26318867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of gut microbiome composition in Iranian patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Abdollahiyan S; Nabavi-Rad A; Keshavarz Azizi Raftar S; Monnoye M; Salarieh N; Farahanie A; Asadzadeh Aghdaei H; Zali MR; Hatami B; Gérard P; Yadegar A
    Sci Rep; 2023 Nov; 13(1):20584. PubMed ID: 37996480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis.
    Gómez-Pérez AM; Ruiz-Limón P; Salas-Salvadó J; Vioque J; Corella D; Fitó M; Vidal J; Atzeni A; Torres-Collado L; Álvarez-Sala A; Martínez MÁ; Goday A; Benaiges D; García-Gavilán J; Bernal López MR; Moreno-Indias I; Tinahones FJ
    Gut Microbes; 2023; 15(1):2223339. PubMed ID: 37345236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut microbiome and nonalcoholic fatty liver diseases.
    Zhu L; Baker RD; Baker SS
    Pediatr Res; 2015 Jan; 77(1-2):245-51. PubMed ID: 25310763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet.
    Mokhtari Z; Gibson DL; Hekmatdoost A
    Adv Nutr; 2017 Mar; 8(2):240-252. PubMed ID: 28298269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Role of gut-liver-immune axis in the pathogenesis of nonalcoholic steatohepatitis].
    Shao L; Song Y; Shi JP
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):505-509. PubMed ID: 34225424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.
    de Faria Ghetti F; Oliveira DG; de Oliveira JM; de Castro Ferreira LEVV; Cesar DE; Moreira APB
    Eur J Nutr; 2018 Apr; 57(3):861-876. PubMed ID: 28875318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Benefit of Bariatric Surgery on Histological Features of Metabolic Associated Fatty Liver Disease Assessed Through Noninvasive Methods.
    Meneses D; Olveira A; Corripio R; Méndez MD; Romero M; Calvo-Viñuelas I; González-Pérez-de-Villar N; de-Cos-Blanco AI
    Obes Surg; 2022 Aug; 32(8):2682-2695. PubMed ID: 35697996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms linking bariatric surgery to adipose tissue, glucose metabolism, fatty liver disease and gut microbiota.
    Latteri S; Sofia M; Puleo S; Di Vincenzo A; Cinti S; Castorina S
    Langenbecks Arch Surg; 2023 Feb; 408(1):101. PubMed ID: 36826628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intestinal microbiota and nonalcoholic steatohepatitis.
    Brandl K; Schnabl B
    Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Links between gut microbiome, metabolome, clinical variables and non-alcoholic fatty liver disease severity in bariatric patients.
    Schwenger KJP; Sharma D; Ghorbani Y; Xu W; Lou W; Comelli EM; Fischer SE; Jackson TD; Okrainec A; Allard JP
    Liver Int; 2024 May; 44(5):1176-1188. PubMed ID: 38353022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.